The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

GLASGOW, Scotland – A single infusion of zoledronic acid (Aclasta) prevents bone turnover in people at risk of Paget’s disease in an analysis of data from the Zoledronate in the Prevention of Paget’s ...

Protocol amendments made on October 27, 2000, after 254 patients had been enrolled, reduced the dose of zoledronic acid to 4 mg every 6 months and increased the infusion time to 15 minutes, ...

In a 12-month study, 40 men with nonmetastatic prostate cancer who were receiving a GnRH agonist and had T scores more than −2.5 were randomly assigned to zoledronic acid (4 mg intravenously on day 1 ...

Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...